

**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**SCHEDULE 13G**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Palvella Therapeutics, Inc.**

(Name of Issuer)

**Common Stock, \$0.001 par value per share**

(Title of Class of Securities)

**697947109**

(CUSIP Number)

**12/13/2024**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

**SCHEDULE 13G**

**CUSIP No.** 697947109

1	<b>Names of Reporting Persons</b> Samsara BioCapital, L.P.
2	<b>Check the appropriate box if a member of a Group (see instructions)</b> <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)
3	<b>Sec Use Only</b>
4	<b>Citizenship or Place of Organization</b> DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 679,486.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 679,486.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 679,486.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 6.1 %	
12	Type of Reporting Person (See Instructions) PN	

SCHEDULE 13G

CUSIP No.	697947109
-----------	-----------

1	Names of Reporting Persons Samsara BioCapital GP, LLC	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 679,486.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 679,486.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 679,486.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	

11	Percent of class represented by amount in row (9) 6.1 %
12	Type of Reporting Person (See Instructions) OO

SCHEDULE 13G

CUSIP No.	697947109
-----------	-----------

1	<b>Names of Reporting Persons</b> Srinivas Akkaraju
2	<b>Check the appropriate box if a member of a Group (see instructions)</b> <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)
3	<b>Sec Use Only</b>
4	<b>Citizenship or Place of Organization</b> UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:	5 <b>Sole Voting Power</b> 0.00
	6 <b>Shared Voting Power</b> 679,486.00
	7 <b>Sole Dispositive Power</b> 0.00
	8 <b>Shared Dispositive Power</b> 679,486.00
9	<b>Aggregate Amount Beneficially Owned by Each Reporting Person</b> 679,486.00
10	<b>Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)</b> <input type="checkbox"/>
11	Percent of class represented by amount in row (9) 6.1 %
12	Type of Reporting Person (See Instructions) IN

SCHEDULE 13G

Item 1.

- (a) **Name of issuer:**  
Palvella Therapeutics, Inc.
- (b) **Address of issuer's principal executive offices:**  
125 Strafford Ave, Suite 360, , Wayne, PA, 19087.

Item 2.

(a) **Name of person filing:**

The names of the persons filing this report (collectively, the "Reporting Persons") are:

Samsara BioCapital, L.P. ("Samsara LP");  
Samsara BioCapital GP, LLC ("Samsara GP");  
Srinivas Akkaraju ("Dr. Akkaraju");

The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

(b) **Address or principal business office or, if none, residence:**

c/o Samsara BioCapital, LLC  
628 Middlefield Road  
Palo Alto, CA 94301

(c) **Citizenship:**

Samsara LP Delaware  
Samsara GP Delaware  
Dr. Akkaraju United States

(d) **Title of class of securities:**

Common Stock, \$0.001 par value per share

(e) **CUSIP No.:**

697947109

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

- (a)  **Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);**
- (b)  **Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);**
- (c)  **Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);**
- (d)  **Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);**
- (e)  **An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);**
- (f)  **An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);**
- (g)  **A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);**
- (h)  **A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);**
- (i)  **A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);**
- (j)  **A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:**
- (k)  **Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).**

**Item 4. Ownership**

(a) **Amount beneficially owned:**

Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

Samsara LP directly holds 679,486 shares of Common Stock. Samsara GP is the sole general partner of Samsara LP and Dr. Akkaraju is a managing member of Samsara GP. Each of Samsara GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara LP.

(b) **Percent of class:**

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. The percentage set forth in each row 11 is based upon 11,221,307 shares of Common Stock outstanding as of December 13, 2024, as reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on December 16, 2024. %

(c) **Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

**(ii) Shared power to vote or to direct the vote:**

Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

**(iii) Sole power to dispose or to direct the disposition of:**

Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

**(iv) Shared power to dispose or to direct the disposition of:**

Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

**Item 5. Ownership of 5 Percent or Less of a Class.**

**Item 6. Ownership of more than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.**

Not Applicable

**Item 8. Identification and Classification of Members of the Group.**

Not Applicable

**Item 9. Notice of Dissolution of Group.**

Not Applicable

**Item 10. Certifications:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Samsara BioCapital, L.P.

Signature: /s/ Srinivas Akkaraju

Name/Title: By Samsara BioCapital GP, LLC, its General Partner,  
By Srinivas Akkaraju, Managing Member

Date: 12/20/2024

Samsara BioCapital GP, LLC

Signature: /s/ Srinivas Akkaraju

Name/Title: By Srinivas Akkaraju, Managing Member

Date: 12/20/2024

Srinivas Akkaraju

**Signature:** /s/ Srinivas Akkaraju

**Name/Title:** Srinivas Akkaraju

**Date:** 12/20/2024

**Exhibit Information**

Exhibit 99.1 Joint Filing Agreement

JOINT FILING AGREEMENT

We, the undersigned, hereby express our agreement that the Schedule 13G (or any amendments thereto) relating to the Common Stock of Palvella Therapeutics, Inc. is filed on behalf of each of us.

Dated: December 20, 2024

**Samsara BioCapital, L.P.**

By: Samsara BioCapital GP, LLC  
its General Partner

By: /s/ Srinivas Akkaraju  
Name: Srinivas Akkaraju  
Title: Managing Member

**Samsara BioCapital GP, LLC**

By: /s/ Srinivas Akkaraju  
Name: Srinivas Akkaraju  
Title: Managing Member

/s/ Srinivas Akkaraju  
Srinivas Akkaraju